Luspatercept is emerging as a frontline option for lower-risk MDS patients, offering sustained transfusion independence with ...

Myelodysplastic syndromes (MDS) are blood cancers that reduce healthy blood cell production, leading to anemia, bleeding, fatigue, and frequent infections. Treatments target the affected blood counts, ...

A phase 2 study of ofirnoflast showed 67% overall hematologic improvement and 55% transfusion independence in ESA-refractory lower-risk MDS.

Myelodysplastic syndrome (MDS) is independently associated with incident cardiovascular disease (CVD), according to a study published online Nov. 10 in the Canadian Journal of Cardiology. Hiroyuki ...

Selected coverage of myelodysplastic syndromes and myeloproliferative disease at the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, California.

Over the past few decades, advances in hematology have illuminated how a delicate balance between stem cell self-renewal and differentiation sustains healthy blood formation. In myelodysplastic ...

Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial We analyzed a cohort ...

Successful Management of Neutropenic Sepsis Is Key to Better Survival of Patients With Blood Cancer in Sri Lanka: Real-World Data From the Resource-Limited Setting Myelodysplastic syndromes (MDS) ...

As of the data cutoff date of April 10, 2026, 30 patients received BH-30236 monotherapy at doses ranging from 5 to 120 mg on a continuous daily administration schedule (QD), and 18 patients received ...